Dr. Reddy's Laboratories
(NYSE) RDY
Dr. Reddy's Laboratories Financials at a Glance
Market Cap
$11.18B
Revenue (TTM)
$345.83B
Net Income (TTM)
$56.59B
EPS (TTM)
$0.78
P/E Ratio
17.23
Dividend
$0.09
Beta (Volatility)
0.43 (Low)
Dividend
$0.09
Beta (Volatility)
0.43 (Low)
Price
$13.26
Volume
63,693
Open
$13.47
Price
$13.26
Volume
63,693
Open
$13.47
Previous Close
$13.26
Daily Range
$13.21 - $13.47
52-Week Range
$12.77 - $16.17
Dividend
$0.09
Beta (Volatility)
0.43 (Low)
Price
$13.26
Volume
63,693
Open
$13.47
Previous Close
$13.26
Daily Range
$13.21 - $13.47
52-Week Range
$12.77 - $16.17
RDY News
What Is an Emerging Market Economy?
Is Dr. Reddy's Laboratories a Buy?
RDY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Dr. Reddy's Laboratories
Industry
Pharmaceuticals
Sector
Health CareEmployees
27,811
CEO
Erez Israeli, MBA
Website
www.drreddys.comHeadquarters
Hyderabad, 500034, IN
RDY Financials
Key Financial Metrics (TTM)
Gross Margin
55%
Operating Margin
19%
Net Income Margin
16%
Return on Equity
18%
Return on Capital
17%
Return on Assets
10%
Earnings Yield
5.80%
Dividend Yield
0.68%
Payout Ratio
11.77%
Stock Overview
Market Cap
$11.18B
Shares Outstanding
832.41M
Volume
63.69K
Avg. Volume
2.29M
Financials (TTM)
Gross Profit
$190.43B
Operating Income
$71.84B
EBITDA
$96.67B
Operating Cash Flow
$46.43B
Capital Expenditure
$34.40B
Free Cash Flow
$12.03B
Cash & ST Invst.
$57.91B
Total Debt
$46.77B
Dr. Reddy's Laboratories Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$87.27B
+4.4%
Gross Profit
$46.81B
-4.6%
Gross Margin
53.63%
N/A
Market Cap
$11.18B
N/A
Market Cap/Employee
$413.31K
N/A
Employees
27,048
N/A
Net Income
$12.10B
-14.4%
EBITDA
$19.56B
-19.4%
Quarterly Fundamentals
Net Cash
$14.86B
+83.6%
Accounts Receivable
$124.27B
+11.5%
Inventory
$79.01B
+10.3%
Long Term Debt
$11.61B
+53.2%
Short Term Debt
$56.12B
+29.0%
Return on Assets
10.05%
N/A
Return on Invested Capital
16.53%
N/A
Free Cash Flow
$3.59B
+263.2%
Operating Cash Flow
$10.91B
+64.8%